Research and Clinical Trials

SWOG 0727: Gemcitabine and Erlotinib With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery
Brief Description  
This randomized phase I/II trial is studying the side effects and best dose of monoclonal antibody therapy when given together with gemcitabine and erlotinib and to see how well they work compared with giving gemcitabine and erlotinib alone as first-line therapy in treating patients with metastatic pancreatic cancer that cannot be removed by surgery.
Who may be Eligible  
Inclusion Criteria:
  • Histologically or cytologically confirmed diagnosis of pancreatic cancer
  • Stage IV disease that is not amendable to surgery
  • Measurable and/or nonmeasurable disease
Exclusion Criteria:
  • No prior chemotherapy, hormonal therapy, immunotherapy, or chemoradiotherapy for advanced   or locally advanced pancreatic cancer, including drugs that target either EGFR or IGFR
  • No plans to receive concurrent chemotherapy, hormonal therapy, radiotherapy, immunotherapy, or any other type of therapy for treatment of cancer
  • No prior gemcitabine hydrochloride
  • No prior chimerized or murine monoclonal antibody therapy
  • No endocrine or neuroendocrine tumors, lymphoma of the pancreas, or ampullary cancer
  • No clinically significant ascites
  • No known brain metastases
Gastrointestinal Cancer
IRB Number  
Principal Investigator  
Salmon, Stuart

For More Information, Contact  Delois  , DeShazo
Phone:  (704) 355-1342  Fax:  (704) 355-1353  
Address:100 South Tryon Street Suite 220